The peripheral monocyte count is associated with the density of tumor-associated macrophages in the tumor microenvironment of colorectal cancer: a retrospective study

Masatsune Shibutani*, Kiyoshi Maeda, Hisashi Nagahara, Tatsunari Fukuoka, Shigetomi Nakao, Shinji Matsutani, Kosei Hirakawa and Masaichi Ohira

Abstract

Background: Inflammation is widely recognized to play an important role in cancer progression, and the peripheral monocyte count has been reported to correlate with the prognosis in patients with colorectal cancer. This is based on the hypothesis that the peripheral monocyte level and the density of tumor-associated macrophages (TAMs) in the cancer microenvironment correlate with each other. However, the influence of TAMs on the prognosis and the correlation between the peripheral monocyte count and the density of TAMs have not yet been elucidated.

Methods: A total of 168 patients with stage II/III colorectal cancer were enrolled in this study. Preoperative blood samples were obtained at the time of the diagnosis before surgery. The expression of TAMs in the cancer microenvironment was assessed by immunohistochemistry.

Results: The progression-free and overall survival rate were significantly worse in the high-TAMs group than in the low-TAMs group (p = 0.0012 and p = 0.0207, respectively). The peripheral monocyte count was significantly associated with the number of TAMs (correlation coefficients: 0.202, p = 0.047).

Conclusions: The peripheral monocyte count was associated with the density of the TAMs, which created a microenvironment favorable for cancer development and were correlated with a poor prognosis. Therefore, the peripheral monocyte count is a useful prognostic marker reflecting the status of the tumor microenvironment.

Keywords: Colorectal cancer, Monocyte, Tumor-associated macrophage

Background

Inflammation is widely recognized to play an important role in cancer progression [1], and various inflammatory markers have been reported as useful prognostic markers in patients with various types of cancer [2–6]. The peripheral monocyte count, which is one such inflammatory marker, has been reported to correlate with the prognosis in patients with prostate, breast and colorectal cancer [7–9]. Moreover, in our previous study, the same results were obtained in colorectal cancer [10]. Tumor-associated macrophages (TAMs) are macrophages that exist within the tumor microenvironment and are derived from circulating monocytes [11, 12]. There are two kinds of macrophage phenotypes: the M1 phenotype has antitumor activity, whereas the M2 phenotype promotes cancer progression [13, 14]. Most TAMs have an M2-like phenotype and promote metastasis, angiogenesis, and immunosuppression [15].

The concept of the peripheral monocyte count being a useful prognostic marker in cancer patients is based on the hypothesis that the peripheral monocyte count...
reflects the density of TAMs in the cancer microenvironment [9, 10, 16]. However, the influence of TAMs on the prognosis and the correlation between the peripheral monocyte count and the density of TAMs have not been elucidated.

In this study, we evaluated the prognostic significance of TAMs and clarified the correlation between the peripheral monocyte count and the density of TAMs in patients with colorectal cancer.

**Methods**

**Patients**

A total of 168 patients with stage II/III colorectal cancer were enrolled in this study. All patients underwent potentially curative surgery for colorectal cancer at the Department of Surgical Oncology of Osaka City University between 2007 and 2009. Patients who received preoperative therapy, underwent emergency surgery for perforation/obstruction, or who had inflammatory bowel disease were excluded from this study.

The patient characteristics are listed in Table 1. A total of 85 males and 83 females were included in this study. The median age of the patients at the initial surgery was 67 years old (range: 26 to 90 years old). Ninety patients had primary tumors located in the colon, and 78 had primary tumors located in the rectum. The resected specimens were pathologically classified according to the seventh edition of the UICC TNM classification of malignant tumors [17]. The distribution of cancer stages was as follows: stage II, 92 patients; stage III, 76 patients. All patients were followed up regularly with physical and blood examinations, including measurements of the levels of tumor markers, such as carcinoembryonic antigen (CEA) and carbohydrate antigen 19–9 (CA19–9), and mandatory screening using colonoscopy and computed tomography until December 2016 or death.

**Blood sample analysis**

Preoperative blood samples were obtained at the time of the diagnosis before surgery. The differential white blood cell count was analyzed using an XE-5000 hematology analyzer (Sysmex, Kobe, Japan) in accordance with the manufacturer’s protocol.

**Immunohistochemistry**

CD163 has been used as a specific marker to identify M2 macrophages [13, 14]. Surgically resected specimens were retrieved to perform immunohistochemistry. Sections 4 μm in thickness were deparaffined and rehydrated. The sections were then subjected to endogenous peroxidase blocking in 1% H₂O₂ solution in methanol for 15 min. Antigen retrieval was performed by autoclaving the sections at 105 °C for 10 min in Dako Target Retrieval Solution (Dako, Glostrup, Denmark). Serum blocking was performed with 10% normal rabbit serum for 10 min. After H₂O₂ and serum blocking, the slides were incubated with primary mouse monoclonal anti-CD163 antibody (1:200 dilution; Leica Biosystems, Newcastle Upon Tyne, UK) at room temperature for 1 h. The secondary antibody was biotin-labeled rabbit anti-mouse IgG (1:500; Nichirei, Tokyo, Japan). Detection was performed with a DAB kit (Histofine simple stain kit; Nichirei). The sections were counterstained with hematoxylin.

**Immunohistochemical evaluations**

Immunohistochemical evaluations were carried out by two independent pathologists blinded to the clinical
information. The number of immunoreactive macro-
phages at the invasive margin was counted with a light
microscope in a randomly selected field at a magnification
of 400× (Fig. 1). The mean of the values obtained in five
different areas was used for the data analysis. According
to the median TAM value, we set 8.0 as the cut-off value
for the evaluation of TAMs and classified patients into a
high-TAMs group and a low-TAMs group.

Statistical analyses
The significance of the correlations between TAMs and
the clinicopathological characteristics were analyzed
using the \( \chi^2 \) test and Fisher’s exact test. The duration of
the survival was calculated using the Kaplan-Meier
method. Differences in the survival curves were assessed
using the log-rank test. A multivariate analysis was
performed using the Cox proportional hazard model.
Associations between peripheral monocyte count and
the density of TAMs in the tumor microenvironment
were evaluated by Spearman’s rank correlation coeffi-
cient. All of the statistical analyses were conducted
using the SPSS software package for Windows (SPSS
Japan, Tokyo, Japan). \( P \) values of <0.05 were consid-
ered to indicate statistical significance.

Ethical considerations
This research conformed to the provisions of the
Declaration of Helsinki. All patients were informed of
the investigational nature of this study and provided
their written informed consent. This retrospective
study was approved by the ethics committee of Osaka
City University (approved No.926).

Results
Correlations between the density of TAMs and the
clinicopathological factors
The density of TAMs showed no significant relationship
with any of the clinicopathological parameters, except
for the histological type (Table 2).

Survival analyses according to the density of TAMs
The progression-free survival rate was significantly
worse in the high-TAMs group than in the low-TAMs
group \( (p = 0.0012) \) (Fig. 2). The overall survival rate was
also significantly worse in the high-TAMs group than in
the low-TAMs group \( (p = 0.0207) \) (Fig. 3).

Prognostic factors influencing the survival
The correlations between the progression-free survival
and the clinicopathological factors are shown in Table 3.
According to the results of a univariate analysis, the
progression-free survival showed significant relationships
with the density of TAMs \( (p = 0.002) \), lymphatic involve-
ment \( (p = 0.011) \), lymph node metastasis \( (p = 0.001) \),
CEA \( (p = 0.014) \), and CA19–9 \( (p < 0.001) \). A multivari-
ate analysis indicated that the density of TAMs (hazard
ratio: 3.692; 95% confidence interval: 1.743–7.822;
\( p = 0.001) \) and lymph node metastasis (hazard ratio:
2.251; 95% confidence interval: 1.131–4.481; \( p = 0.021) \)
were independent prognostic factors for the progression-
free survival.
The correlations between the overall survival and the
clinicopathological factors are shown in Table 4. Accord-
ing to the results of a univariate analysis, the overall
survival showed significant relationships with the density

---

Fig. 1 The immunohistochemical expression of CD163, an M2 macrophage-specific marker. a A low density of TAMs (100×) b A high density of TAMs (100×) c A low density of TAMs (400×) d A high density of TAMs (400×)
of TAMs ($p = 0.027$), age ($p = 0.036$), venous involvement ($p = 0.010$), lymph node metastasis ($p = 0.024$), CEA ($p = 0.021$), and CA19–9 ($p = 0.017$). A multivariate analysis indicated that the density of TAMs (hazard ratio: 4.123; 95% confidence interval: 1.464–11.610; $p = 0.007$), age (hazard ratio: 3.355; 95% confidence interval: 1.373–8.200; $p = 0.008$), and venous involvement (hazard ratio: 3.911; 95% confidence interval: 1.540–9.936; $p = 0.004$) were independent prognostic factors for the overall survival.

### Table 2

|                      | TAM | p-value |
|----------------------|-----|---------|
|                       | Low | High    |
| Age (years)          |     |         |
| <70                  | 50  | 59      | 0.108  |
| ≥70                  | 35  | 24      |
| Gender               |     |         |
| Male                 | 37  | 47      | 0.089  |
| Female               | 48  | 35      |
| Tumor depth*         |     |         |
| T1–3                 | 58  | 51      | 0.420  |
| T4                   | 27  | 32      |
| Histological type    |     |         |
| Well, moderate       | 82  | 72      | 0.027  |
| Poorly, mucinous     | 3   | 11      |
| Tumor diameter       |     |         |
| <5 cm                | 58  | 49      | 0.262  |
| ≥5 cm                | 27  | 34      |
| Lymphatic involvement|     |         |
| Negative             | 20  | 20      | 1.000  |
| Positive             | 65  | 63      |
| Venous involvement   |     |         |
| Negative             | 70  | 67      | 0.844  |
| Positive             | 15  | 16      |
| Lymph node metastasis|     |         |
| Negative             | 46  | 46      | 0.878  |
| Positive             | 39  | 37      |
| CEA                  |     |         |
| ≤5 ng/ml             | 56  | 49      | 0.426  |
| >5 ng/ml             | 29  | 34      |
| CA19–9               |     |         |
| ≤37 U/ml             | 76  | 71      | 0.211  |
| >37 U/ml             | 6   | 12      |

TAMs tumor-associated macrophages, CEA carcinoembryonic antigen, CA19–9 carbohydrate antigen 19–9

*According to the UICC. TNM Classification of Malignant Tumors (Seventh edition)

Correlation between the peripheral monocyte count and the number of TAMs in the tumor microenvironment
The peripheral monocyte count was significantly associated with the number of TAMs (correlation coefficient: 0.202, $p = 0.047$) (Fig. 4).

### Discussion
We found that a high density of TAMs in the cancer microenvironment was associated with a poor prognosis in patients with colorectal cancer. We also found that the peripheral monocyte count was associated with the density of TAMs in the cancer microenvironment. These results may explain the reason why the peripheral
Monocyte count functions as a prognostic marker in patients with colorectal cancer.

Increasing evidence suggests that stromal cells, such as tumor-infiltrating lymphocytes, TAMs, and cancer-associated fibroblasts, in the cancer microenvironment are associated with cancer progression. TAMs were first reported in the early 1980s [18] and have been extensively studied, with their process of differentiation and function now clear. Monocytes differentiate into macrophages after recruitment from the peripheral blood to the tumor [11, 12, 19]. They can be divided into two main phenotypes: M1 type and M2 type. These polarizations are adjusted by cytokines, such as macrophage-colony-stimulating factor (M-CSF), transforming growth factor (TGF)-β, interleukin (IL)-6 and IL-10 in the cancer microenvironment [20, 21]. M1 macrophages have antitumor activity, whereas M2 macrophages play an important role in invasion, metastasis, angiogenesis, and immunosuppression, which lead to cancer progression [15, 22]. M2-macrophages play an important role in tumor progression and metastasis via angiogenesis through their production of angiogenic factors such as vascular endothelial growth factor (VEGF) [23, 24], and play a role in tumor invasion via a matrix metalloproteinase (MMP)-dependent mechanism through their production of tumor necrosis factor-alpha (TNF-α) [25]. Moreover, M2 macrophages are responsible for immunosuppression through their inhibition of the T cell function via the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway and their production of immunosuppressive cytokines such as interleukin (IL)-10 [26]. Because the majority of TAMs have an M2-like phenotype [27], the high density of TAMs in the cancer microenvironment is associated with a poor prognosis.

In previous reports, the peripheral monocyte count and the lymphocyte-to-monocyte ratio have been reported to be useful prognostic markers [9, 10, 16, 28, 29]. This was based on the hypothesis that the peripheral monocyte count was associated with the density of TAMs in the cancer microenvironment. However, few reports have

### Table 4 Correlations between the overall survival and clinicopathological factors

|                  | Univariate analysis | Multivariate analysis |
|------------------|---------------------|-----------------------|
|                  | HR  | 95% CI          | P-value | HR  | 95% CI          | P-value |
| Age (≥70 years vs. <70 years) | 2.366 | 1.058–5.289 | 0.036 | 3.355 | 1.373–8.200 | 0.008 |
| Gender (Male vs. Female) | 1.250 | 0.565–2.765 | 0.582 |       |                 |        |
| Tumor depth (T4 vs. T1–3) | 1.387 | 0.616–3.124 | 0.430 |       |                 |        |
| Histological type (Poorly, Mucinous vs. Well, Moderately) | 1.660 | 0.495–5.573 | 0.412 |       |                 |        |
| Lymphatic involvement (Positive vs. Negative) | 2.461 | 0.733–8.258 | 0.145 |       |                 |        |
| Venous involvement (Positive vs. Negative) | 2.987 | 1.306–6.831 | 0.010 | 3.911 | 1.540–9.936 | 0.004 |
| Lymph node metastasis (Positive vs. Negative) | 2.641 | 1.135–6.148 | 0.024 | 1.729 | 0.699–4.273 | 0.236 |
| CEA (>5 ng/ml vs. ≤5 ng/ml) | 2.563 | 1.149–5.717 | 0.021 | 1.258 | 0.513–3.085 | 0.616 |
| CA19–9 (>37 U/ml vs. ≤37 U/ml) | 3.117 | 1.226–7.928 | 0.017 | 2.127 | 0.720–6.281 | 0.172 |
| TAM (High vs. Low) | 2.841 | 1.128–7.152 | 0.027 | 4.123 | 1.464–11.610 | 0.007 |

HR hazard ratio, CI confidence interval, TAMs tumor-associated macrophages, CEA carcinoembryonic antigen, CA19–9 carbohydrate antigen 19–9
described the correlation between the peripheral monocyte count and the density of TAMs in the cancer microenvironment. In the present study, the peripheral monocyte count was shown to correlate with the density of TAMs in the cancer microenvironment, suggesting that inflammatory markers such as the peripheral monocyte count might be surrogate markers reflecting the status of the cancer microenvironment. A peripheral blood cell count is a quick, easy, and inexpensive assay to perform and is often carried out as a routine examination. We hope that peripheral inflammatory markers will be applied clinically as biomarkers in patients with colorectal cancer in the future.

The median peripheral monocyte count, which was obtained 5 years after operation from patients who had been relapse free, was 321 (range: 118–504). This value was significantly lower than the preoperative peripheral monocyte count ($p < 0.001$, paired t-test). The mechanism underlying the increase in the peripheral monocyte count of cancer patients is considered to be as follows. Chemokines (such as CCL2), which are produced by cancer cells, promote the recruitment of peripheral monocytes to the cancer microenvironment, thereby promoting the recruitment of monocytes from the bone marrow to peripheral blood.

Several limitations associated with the present study warrant mention. First, we evaluated a relatively small number of patients, and the study design was retrospective. Second, factors other than the response of the host to the cancer, which affect the systemic inflammation, were not assessed. Third, M1 macrophages, which are also derived from circulating monocytes, were not considered in this study, although most macrophages in the cancer microenvironment are reported to be M2 macrophages, and the impact of M1 macrophages on the cancer microenvironment is likely negligible. Fourth, we did not verify the polarization of the macrophages in this study. Further studies are needed to elucidate the mechanisms underlying M1/M2 polarization in the cancer microenvironment. By co-culturing the peripheral monocytes and cancer cell lines, we can confirm that most monocytes polarized to the M2 phenotype in the cancer microenvironment and investigate the types of cytokines that are involved in polarization.

**Conclusions**

In conclusion, our results showed that the peripheral monocyte count was associated with the density of the TAMs, which created a microenvironment favorable for cancer development and were correlated with a poor prognosis, in the cancer microenvironment. Therefore, the peripheral monocyte count is considered to be a useful prognostic marker reflecting the status of the tumor microenvironment.

**Abbreviations**

CA19-9: Carbohydrate antigen 19–9; CEA: Carcinoembryonic antigen; CI: Confidence interval; HR: Hazard ratio; IL: Interleukin; M-CSF: Macrophage-colony-stimulating factor; TAMs: Tumor-associated macrophages; TGF-β: Transforming growth factor-β
Acknowledgements
This research received no specific grants from any funding agency in the public, commercial or not-for-profit sectors. We thank Brian Quinn who provided medical writing services on behalf of JMC, Ltd.

Funding
No funding was acquired for this study.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
MS and KM designed the study, performed the statistical analysis and drafted the manuscript. HN, TF, SN and SM collected the clinical data and revised the manuscript critically. KH and MO designed the study and critically reviewed the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
This research conformed to the provisions of the Declaration of Helsinki. All patients were informed of the investigational nature of this study and provided their written informed consent. This retrospective study was approved by the ethics committee of Osaka City University (approved No.926).

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 17 March 2017 Accepted: 30 May 2017
Published online: 05 June 2017

References
1. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.
2. Baba H, Kuwabara K, Ishiguro T, Hatano S, Matsuzawa T, Fukushima M, et al. C-reactive protein as a significant prognostic factor for stage IV gastric cancer patients. Anticancer Res. 2013;33:5991–5.
3. Shibutani M, Maeda K, Nagahara H, Nozoe E, Ohtani H, Nishiguchi Y, et al. A high preoperative neutrophil-to-lymphocyte ratio is associated with poor survival in patients with colorectal cancer. Anticancer Res. 2013;33:3291–4.
4. Luo G, Guo M, Liu Z, Xiao Z, Jin K, Long J, et al. Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. Ann Surg Oncol. 2015;22:670–6.
5. Fan H, Shao ZY, Xiao YF, Xie ZH, Chen W, Xie H, et al. Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer. J Cancer Res Clin Oncol. 2016;142:1285–97.
6. Shibutani M, Maeda K, Nagahara H, Iseki Y, Ikeya T, Hirakawa K. Prognostic significance of the preoperative ratio of C-reactive protein to albumin in patients with colorectal cancer. Anticancer Res. 2016;36:995–1001.
7. Shigeta K, Kosaka T, Kitano S, Yasumizu Y, Miyazaki Y, Minozou R, et al. High absolute monocyte count predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy. Ann Surg Oncol. 2016;23:4115–22.
8. He J, Lv P, Yang X, Chen Y, Liu C, Qiu X. Pretreatment lymphocyte to monocyte ratio as a predictor of prognosis in patients with early-stage triple-negative breast cancer. Tumor Biol. 2016;37:9037–43.
9. Chan JC, Chan DL, Diakos CI, Engel A, Pavlakis N, Gill A, et al. The Lymphocyte-to-monocyte ratio is a superior predictor of overall survival in comparison to established biomarkers of resectable colorectal cancer. Ann Surg. 2017;265:539–46.
10. Shibutani M, Maeda K, Nagahara H, Ikeki Y, Ikeya T, Hirakawa K. Prognostic significance of the preoperative lymphocyte-to-monocyte ratio in patients with colorectal cancer. Oncol Lett. 2017;13:1000–6.
11. Gosselin D, Link VM, Romanowski CE, Fonseca GJ, Eichenfield DF, Spann NJ, et al. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell. 2014;159:1527–40.
12. Marech I, Ammedola M, Sacco R, Sammarco G, Zuccalà V, Zizzo N, et al. Tumour-associated macrophages correlate with microvascular bed extension in colorectal cancer patients. J Cell Mol Med. 2016;20:1373–80.
13. Maniecki MB, Etzerodt A, Ulhøi JP, Steineiche T, Borre M, Dynskjæt L, et al. Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells. Int J Cancer. 2012;131:2320–31.
14. Richards DM, Hettinger J, Feurer M. Monocytes and macrophages in cancer: development and functions. Cancer Microenviron. 2013;6:179–91.
15. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell. 2013;23:277–86.
16. Shibutani M, Maeda K, Nagahara H, Ohtani H, Sakuai K, Yamazoe S, et al. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with metastatic colorectal cancer. World J Gastroenterol. 2015;21:9966–73.
17. Sobin LH, Gospodarowicz MK, Wittekind C. UICC. TNM Classification of Malignant Tumors. Seventh edition. New York: Wiley-Liss; 2009.
18. Badawi MA, Abouelfadl DM, El-Sharkawy SL, El-Aal WE, Abbas NF. Tumor-Associated Macrophage (TAM) and angiogenesis in human colon carcinoma. Open Access Maced J. Med Sci. 2015;3:209–14.
19. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. The origin and function of tumour-associated macrophages. Immunol Today. 1992;13:265–70.
20. Zhang F, Wang W, Wang X, Jiang G, Liu H, Zhang G, et al. TGF-β induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype. Onco Targets. 2016;5:2294–306.
21. Sica A, Schoppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006;42:717–27.
22. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549–55.
23. Kimura YN, Watari K, Fotovati A, Hosoi F, Yasumoto K, Izumi H, et al. Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis. Cancer Sci. 2007;98:2009–18.
24. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–57.
25. Hagemann T, Robinson SC, Schulz M, Trümper L, Balkwill FR, Binder C. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis. 2004;25:1543–9.
26. Mantovani A, Allavena P. The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med. 2015;212:435–45.
27. He NF, Zhang L, Huang CF, Ma SR, Wang YT, Wang WM, et al. CD163+ tumor-associated macrophages correlated with poor prognosis and cancer stem cells in oral squamous cell carcinoma. Biomed Res Int. 2014;2014:838632.
28. Stotz M, Pichler M, Absenger G, Szkandera J, Arminger F, Schaberl-Moser R, et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer. 2014;110:435–40.
29. Hu P, Shen H, Wang G, Zhang P, Liu Q, Ju D. Prognostic significance of systemic inflammation-based lymphocyte- monocyte ratio in patients with lung cancer: based on a large cohort study. PLoS One. 2014;9:e108602.